Five IPOs raised $1.4 billion this week, bringing the year's total up to 50 IPOs raising $15 billion. Set to be the week's largest offerings, two energy companies struggled: Antero Midstream GP broke issue while Liberty postponed. A mortgage REIT and...read more
Ovid Therapeutics, an early stage biotech developing treatments for rare neurodevelopmental disorders, raised $75 million by offering 5 million shares at $15, the low end of the range of $15 to $17. Ovid Therapeutics plans to list on the Nasdaq under the...read more
The IPO market continues to heat up with six deals on the calendar aiming to raise $1.7 billion in the first week of May. They include three biotechs, two energy companies and one mortgage REIT. This April was the busiest month for IPOs in almost two years, and ...read more
Ovid Therapeutics, a clinical-stage biotech developing treatments for rare neurological disorders, announced terms for its IPO on Tuesday.
The New York, NY-based company plans to raise $80 million by offering 5 million shares at a price range of $15 to $17....read more
US IPO Weekly Recap: Biotechs and energy fail to excite in 5-IPO week
Five IPOs raised $1.4 billion this week, bringing the year's total up to 50 IPOs raising $15 billion. Set to be the week's largest offerings, two energy companies struggled: Antero Midstream GP broke issue while Liberty postponed. A mortgage REIT and...read more
Ovid Therapeutics prices IPO at $15, the low end of the range
Ovid Therapeutics, an early stage biotech developing treatments for rare neurodevelopmental disorders, raised $75 million by offering 5 million shares at $15, the low end of the range of $15 to $17. Ovid Therapeutics plans to list on the Nasdaq under the...read more
US IPO Week Ahead: May starts strong with 6 IPOs featuring energy and biotech
The IPO market continues to heat up with six deals on the calendar aiming to raise $1.7 billion in the first week of May. They include three biotechs, two energy companies and one mortgage REIT. This April was the busiest month for IPOs in almost two years, and ...read more
Rare neurological disorder biotech Ovid Therapeutics sets terms for $80 million IPO
Ovid Therapeutics, a clinical-stage biotech developing treatments for rare neurological disorders, announced terms for its IPO on Tuesday. The New York, NY-based company plans to raise $80 million by offering 5 million shares at a price range of $15 to $17....read more